MedinCell SA stock analysis
Want to see FR:MEDCL full AI Analyst Report?
MedinCell SA (MEDCL) Stock Price & Analysis
MEDCL Stock Chart & Stats
- Day’s Range
- EUR 29.30 - EUR 29.96
- 52-Week Range
- EUR 19.69 - EUR 32.38
- Previous Close
- EUR 29.76
- Volume
- N/A
- Average Volume (3M)
- 146.19K
- Market Cap
- EUR 1.07B
- Enterprise Value
- EUR 731.65M
- Total Cash (Recent Filing)
- EUR 84.82M
- Total Debt (Recent Filing)
- EUR 57.41M
- Price to Earnings (P/E)
- ―
- Beta
- 0.78
- Next Earnings
- Dec 09, 2026 (Est.)
- EPS Estimate
- -0.11
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Recurring Royalty Growth
The rising royalty mix makes revenue more recurring and less dependent on individual milestones. Strong UZEDY sales growth also validates partner commercialization and can improve revenue quality as royalties compound over the coming quarters.
Olanzapine Regulatory Progress
Acceptance of the U.S. filing and submission in Europe materially advance a potential second royalty-generating product. If approved, olanzapine could diversify MedinCell's commercial base and create a new growth engine from late 2026 onward.
Expanding Partnered Pipeline
A broad formulation pipeline and multiple partners increase the number of potential future products using BEPO technology. Partner funding and AbbVie's advancing program also provide external validation while helping distribute development and commercialization responsibilities.
Bears Say
Persistent And Widening Losses
Deepening losses show that revenue growth has not yet translated into operating leverage. Continued investment may support the pipeline, but sustained negative margins reduce internal funding capacity and keep future profitability dependent on successful product ramps.
Cash Burn And Thin Equity
The return to substantial cash consumption increases reliance on liquidity, future royalties, or external funding to sustain development. Thin equity provides a limited accounting buffer, making execution setbacks more consequential despite reported zero debt.
Partner And Regulatory Dependence
MedinCell's growth model relies on partners to commercialize products and advance selected programs, limiting direct control over timing and market execution. Regulatory pathway changes or delayed partner decisions could postpone royalties and weaken the expected pipeline progression.
MedinCell SA News
MEDCL FAQ
What was MedinCell SA’s price range in the past 12 months?
What is MedinCell SA’s market cap?
When is MedinCell SA’s upcoming earnings report date?
How were MedinCell SA’s earnings last quarter?
Is MedinCell SA overvalued?
Does MedinCell SA pay dividends?
What is MedinCell SA’s EPS estimate?
How many shares outstanding does MedinCell SA have?
What happened to MedinCell SA’s price movement after its last earnings report?
Which hedge fund is a major shareholder of MedinCell SA?
What is the TipRanks Smart Score and how is it calculated?
Company Description
MedinCell SA
MedinCell S.A. specializes in pioneering diverse therapeutic treatments. At the core of its development lies BEPO, a cutting-edge technology that enables the creation of long-acting injectable pharmaceutical products. This system leverages a unique combination of proprietary copolymers and a biocompatible solvent to effectively dissolve or suspend active drug compounds. The company's advanced pipeline includes several key products: mdc-IRM, a subcutaneous injection currently in Phase III clinical trials for the treatment of schizophrenia; mdc-CWM, an intra-articular injection designed to address pain and inflammation; and mdc-TJK, another subcutaneous injection targeting schizophrenia, presently in preclinical development. MedinCell is also actively engaged in formulation research for additional product candidates. These encompass subcutaneous injections such as mdc-WWM for contraception, mdc-ANG for central nervous system-related conditions, mdc-ELK for depression, and mdc-GRT for organ transplant applications. Furthermore, the firm is investigating perineural injections like mdc-CMV for anesthesia and pain management, and mdc-NVA, also intended for pain relief. MedinCell S.A. maintains its headquarters in Jacou, France.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Christophe Douat
- Employees
- 141
- Website
- www.medincell.com
- Address
- 3 rue des Frères Lumière, Jacou, OC, 34830, FR
MedinCell SA (MEDCL) Earnings & Revenues
MEDCL Earnings Call
Earnings Call SentimentPositive
The call presents a largely positive strategic picture: strong commercial traction for UZEDY with high-teens to double-digit growth rates, clear regulatory progress for olanzapine LAI (NDA accepted) and an expanding partnered pipeline (15 formulation-stage programs, AbbVie program advancing toward clinic). Management is intentionally increasing investment to accelerate R&D and business development, which drove higher operating expenses and resulted in an operating and net loss this fiscal year, and there are near-term accounting and FX headwinds (non-cash EIB warrant revaluation, USD exposure) as well as some program-specific regulatory uncertainty. Overall, the company is in a transitional, investment-heavy phase with improving recurring royalty revenue that supports a positive outlook if commercial ramps and regulatory approvals proceed as expected.
View all FR:MEDCL earnings summariesMEDCL Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 14 | 3 | 5 |
| Technical Analysis | 2 | 3 | 5 |
| Moving Averages | 12 | 0 | 0 |
